Advertisement

Journal of Chemical Crystallography

, Volume 38, Issue 1, pp 27–31 | Cite as

Synthesis of 7,4′-Bis-(hydroxyl)-8,3′,5′-tris-(hydroxymethyl)isoflavone and Crystal Structure of its Ester

  • Yun He
  • Li-Li Chen
  • Zun-Ting Zhang
Original Paper

Abstract

7,4′-bis-(hydroxyl)-8,3′,5′-tris-(hydroxymethyl)isoflavone (I) and its ester were synthesized and examined by IR, element analysis and 1H NMR. The crystal of 7,4′-bis-(acetyl oxide)-8,3′,5′-tris-(acetoxymethyl)isoflavone (II) was studied by X-ray diffraction. (II) crystallizes in the monoclinic with space group P2 1 /c. a = 17.987(3) Å, b = 17.972(3) Å, c = 8.4087(11) Å, β = 97.703(3)°, V = 2693.7(6) Å3 and Z = 4. The molecular structure of the ester consists of a benzopyranone moiety, a phenyl moiety, two acetyl oxides and three acetoxymethyl groups. Hydrogen bonds and aromatic stacking interactions link the ester into a two-dimensional structure.

Index Abstract

7,4′-bis-(hydroxyl)-8,3′,5′-tris-(hydroxymethyl)isoflavone and its ester were synthesized and examined by IR, element analysis and 1H NMR. The result of the ester’s crystal structure showed that hydrogen bonding and aromatic π–π stacking assemble the ester into a two-dimensional networking structure.

Keywords

7,4′-Bis-(hydroxyl)-8,3′,5′-tris-(hydroxymethyl)isoflavone 7,4′-Bis-(acetyloxide)-8,3′,5′-tris-(acetoxymethyl)isoflavone Crystal structure π–π stacking interaction Hydrogen bond 

Notes

Acknowledgment

The authors thank the Science and Technology Key Project of Education Ministry, P.R. China (No: 07138) for financial support.

References

  1. 1.
    Fan LL, Zhao DH, Zhao MQ, Zeng GY (1985) Acta Pharm Sin 20:647–651Google Scholar
  2. 2.
    Meng QH, Philip L, Kristina W (1999) Biochim Biophys Acta 1438:369–376Google Scholar
  3. 3.
    Tlkkanen MJ, Wahala K, Ojala S, Vihtna V, Adletcteutr H (1998) Proc Nat Acad Sci 95:3106–3110CrossRefGoogle Scholar
  4. 4.
    Guo JP, Sun QR, Zhuo Q (1995) Chin Tradit Herb Drugs 26:163–165Google Scholar
  5. 5.
    Jing YK (1992) Chin J Pharmacol Toxicol 6:278–280Google Scholar
  6. 6.
    Sarhyyamoonhy N, Wang TY (1997) Euro J Cancer 14:2384– 2389Google Scholar
  7. 7.
    Jing YK, Nakaya K, Han R (1993) Anticancer Res 13:1049–1056Google Scholar
  8. 8.
    Emi S, Masayoshi Y (2000) Biochem Pharmacol 59:471–475CrossRefGoogle Scholar
  9. 9.
    Miksicek RJ (1993) Mol Pharmacol 44:37–43Google Scholar
  10. 10.
    Daigo K, Japan Pat., 7232074, 1972-08-1Google Scholar
  11. 11.
    Daigo K, Japan Pat., 7248387, 1972-10-06Google Scholar
  12. 12.
    Daigo K, Japan Pat., 7246067, 1972-11-20Google Scholar
  13. 13.
    Daigo K, Japan Pat., 7310076, 1973-02-08Google Scholar
  14. 14.
    Sheldrick GM (1997) SHELXS97. Program package for crystal structure solution and refinement. University of Göttingen, GermanyGoogle Scholar
  15. 15.
    Janiak C (2000) J Chem Soc Dalton Trons 3885–3896Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.School of Chemistry and Materials ScienceShaanxi Normal UniversityXi’anPeople’s Republic of China

Personalised recommendations